PACK IN HAND · ONE-PAGE CHECK
Medicine pack check sheet
Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.
Published record starting point
- Record display name
- ZOFRAN / ZOFRAN ODT
- Generic name / active ingredient
- ondansetron
- Dosage-form class
- Conventional oral tablets, orally disintegrating tablets and 4 mg/5 mL oral solution must be identified separately. The 24 mg conventional tablet is an historical Orange Book product identity and is not listed among the available dosage forms and strengths in the current 2025 label
- Route
- Oral
- Record reviewed
- 2026-08-29
Copy from the pack in hand
Source-linked reading points
- Conventional tablets and ODTs may both say 4 mg or 8 mg, but their dosage form and handling differ. Keep ZOFRAN ODT in its blister until use, peel back the foil with dry hands, gently remove it rather than push the fragile tablet through the foil, and place it on the tongue immediately to dissolve. This is not an individual frequency or dosage-form switching rule.
- ZOFRAN ODT contains aspartame and supplies a small amount of phenylalanine. A person with phenylketonuria or a caregiver should verify the exact form and current label; conventional-tablet or solution information does not replace this ODT ingredient warning.
- The label warns about QT prolongation. Avoid use in congenital long-QT syndrome; low potassium or magnesium, congestive heart failure, bradyarrhythmia or another QT-prolonging medicine requires professional review and the label may call for ECG monitoring. Do not add, reduce, separate or stop any medicine from this page.
- Serotonin syndrome may occur with serotonergic medicines, including some SSRIs, SNRIs, other antidepressants, triptans, tramadol, lithium, fentanyl and St John's wort. A combination of agitation, mental-status change, rapid heartbeat, blood-pressure change, fever, sweating, tremor, muscle rigidity or diarrhoea needs immediate medical assessment; use local emergency services if severe.
Reviewed presentation examples — compare every field
- Ondansetron 4 mg per tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020103 / Product 001
- Ondansetron 8 mg per tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020103 / Product 002
- Ondansetron 24 mg per tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020103 / Product 003
- Ondansetron 4 mg per orally disintegrating tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020781 / Product 001
- Ondansetron 8 mg per orally disintegrating tablet; historical RLD currently listed as Discontinued in the Orange BookNDA 020781 / Product 002
- Ondansetron 4 mg per 5 mL; this is a concentration, not an individual's millilitresNDA 020605 / Product 001